Drugs / LVgp120duoCAR-T cells
LVgp120duoCAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04648046 | Mar 2021 → Dec 2028 expected | HIV infectious disease | Steven Deeks | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LVgp120duoCAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04648046 ↗ |
| Known as | anti-HIV duoCAR T cells | “Here we show that i.v. injected anti-HIV duoCAR T cells, generated using a clinical-grade anti-HIV duoCAR lentiviral vector, localized to the site of active HIV infection in...” PMID 36345941 ↗ Nov 2022 |
| Known as | duoCAR T cells | “Here we show that i.v. injected anti-HIV duoCAR T cells, generated using a clinical-grade anti-HIV duoCAR lentiviral vector, localized to the site of active HIV infection in...” PMID 36345941 ↗ Nov 2022 |
| Modality | Cell therapy | “HIV-specific chimeric antigen receptor-T cell (CAR T cell) therapies” PMID 36345941 ↗ Nov 2022 |
| Route | Intravenous | “i.v. injected anti-HIV duoCAR T cells” PMID 36345941 ↗ Nov 2022 |